Breast Cancer
Conditions
Interventions
Observational Group:None
Sponsors
The Affiliated Hospital of Xuzhou Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Case detection-confirmed HER2-positive invasive breast cancer, consistent with adjuvant therapy indications; HER2-positive is defined as HER2 3+ by immunohistochemical staining (IHC) or positive by fluorescence in situ hybridization (FISH); 2. ECOG score 0-2; 3.>=4 cycles of enito-based regimen; consistent and complete data information available in the medical records system;
Exclusion criteria
Exclusion criteria: 1. Prior systemic treatment for any other malignancy; incompliant patients with psychiatric disorders or psychotropic substance abuse; 2. Patients with secondary malignant tumors; 3. Patients with poor compliance (2 non-tolerated unexplained discontinuations); 4. Clinical data were missing seriously, including general condition, laboratory examination results, imaging examination results and follow-up conditions, which were insufficient to evaluate the efficacy and adverse reactions of patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease-free survival;Recurrence rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety;Overall Survival; | — |
Countries
China
Contacts
Public ContactHan Zhengxiang
The Affiliated Hospital of Xuzhou Medical University
Outcome results
None listed